Funding allows advancement of diverse programs through multiple clinical data readouts, including multiple indications for lead candidatefelzartamab
SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ --Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company developing targeted therapies for patients withsevere immune-mediated diseases (IMDs), today announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global. Viking Global Investors and Arkin Bio Capital participated in the financing, as well as existing investors Jeito Capital and ARCH Venture Partners.
"These funds allow us to advancefelzartamab, our clinically differentiated lead therapeutic candidate, through clinical readouts in multiple indications and preparation for registrational studies," said Travis Murdoch, M.D., CEO of HI-Bio. "We are encouraged by promising clinical data to date for felzartamab and its anti-CD38 cell depletion approach, and we look forward to new data, including Phase 2 results from an investigator-initiated trial for antibody-mediated rejection in kidney transplant patients."
Since the company's launch, HI-Bio has advancedfelzartamab, a monoclonal antibody targeting CD38 and in-licensed from MorphoSys, across indications including antibody-mediated rejection (AMR), IgA nephropathy (IgAN), lupus nephritis (LN) and primary membranous nephropathy (PMN). Felzartamab has received Breakthrough Therapy Designation and Orphan Drug Designation from the U.S. Food and Drug Administration in PMN. HI-Bio has also initiated a clinical study of HIB210, an anti-C5aR1 candidate targeting neutrophil activation and chemotaxis.
"Immune-mediated diseases contribute to an immense disease burden which drives the need for novel targeted treatments to improve on existing therapies," said Chris Dimitropoulos, Managing Director of Healthcare Investments at Alpha Wave Global. "HI-Bio is generating compelling clinical data demonstrating the differentiated potential of felzartamab; we look forward to continued progress for felzartamab across multiple indications with high unmet need."
Funding from the Series B will be used to advance clinical development offelzartamab, to evaluate the clinical properties of HIB210 in healthy volunteers and to advance a discovery-stage program targeting mast cell dysfunction toward IND-enabling studies. In conjunction with the financing, the company announced that Chris Dimitropoulos, Managing Director of Healthcare Investments at Alpha Wave Global, has been appointed to the HI-Bio Board of Directors.
About HI-Bio Human Immunology Biosciences, Inc. (HI-Bio) is a clinical-stage biotechnology companyfocused on discovering and developing precision medicines for people suffering from immune-mediated diseases (IMDs). HI-Bio is leading clinical immunology into its next chapter by targeting cellular drivers of disease. To learn more about HI-Bio, visit us at http://www.hibio.com or follow us on LinkedIn and Twitter.
SOURCE HI-Bio
See original here:
HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases - PR Newswire
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]
- Smoking has long-term effects on the immune system - Institut Pasteur - February 21st, 2024 [February 21st, 2024]
- Spring Allergies Attack More Than Just Your Nose - ACAAI Public Website - American College of Allergy Asthma and Immunology - February 21st, 2024 [February 21st, 2024]
- Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Shikhar Mehrotra named co-leader of Cancer Biology and Immunology research program at MUSC Hollings - The Cancer Letter - January 27th, 2024 [January 27th, 2024]
- Gut Microbiome Benefits of Breast Milk Revealed in Mouse Study - Technology Networks - January 27th, 2024 [January 27th, 2024]
- Research on Immunological Diseases Launches with Hungarian Participation - Hungary Today - January 27th, 2024 [January 27th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Associated Press - January 8th, 2024 [January 8th, 2024]
- TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration - Business Wire - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former Westside Pavilion into centers for research on immunology and quantum science - KABC-TV - January 8th, 2024 [January 8th, 2024]
- Beyond Cytotoxicity: The Importance of T Cell Memory - The Scientist - January 8th, 2024 [January 8th, 2024]
- IKAROS: Unlocking the secrets of the immune system's key player - News-Medical.Net - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Caledonian-Record - January 8th, 2024 [January 8th, 2024]
- Revolutionizing Vaccine Research: The Power of a New Algorithm - SciTechDaily - December 31st, 2023 [December 31st, 2023]
- Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people ... - Nature.com - December 22nd, 2023 [December 22nd, 2023]
- Two new practice parameters offer recommendations for treating anaphylaxis and atopic dermatitis - News-Medical.Net - December 22nd, 2023 [December 22nd, 2023]
- Physician and Patient (Un)Wellness in Allergy and Immunology During COVID-19 and Beyond: Lessons for the Future - Physician's Weekly - December 22nd, 2023 [December 22nd, 2023]
- Researchers Identify Why Some Cancers Do Not Respond to Immunotherapy - NYU Langone Health - December 22nd, 2023 [December 22nd, 2023]
- MU's Haval Shirwan recognized for achievements in immunology - Columbia Daily Tribune - December 22nd, 2023 [December 22nd, 2023]
- Parker Institute for Cancer Immunotherapy (PICI) Welcomes Weill Cornell Medicine to Cancer Research Consortium - Weill Cornell Medicine Newsroom - December 14th, 2023 [December 14th, 2023]
- Annals of Allergy, Asthma and Immunology Examines Effects of Climate Change on Allergic Conditions - Newswise - December 14th, 2023 [December 14th, 2023]
- British Society for Immunology response to the NHS vaccination strategy - British Society for Immunology | - December 14th, 2023 [December 14th, 2023]
- NYU Langone Health in the NewsFriday, December 8, 2023 - NYU Langone Health - December 14th, 2023 [December 14th, 2023]
- Arturo Casadevall Named Distinguished Fellow by the American Association of Immunologists - Johns Hopkins Bloomberg School of Public Health - December 14th, 2023 [December 14th, 2023]
- ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scien - PharmiWeb.com - December 14th, 2023 [December 14th, 2023]
- Ishares Genomics Immunology And Healthcare Etf ($IDNA) Proactive Strategies - Stock Traders Daily - December 14th, 2023 [December 14th, 2023]
- Medical Breakthroughs Fueling Infection Prevention Market: Immunology and Modern Medicine Advancements to ... - PR Newswire - December 14th, 2023 [December 14th, 2023]
- Cancer therapy bexmarilimab awakens immune cells to attack tumors that have avoided the detection of the immune ... - EurekAlert - December 14th, 2023 [December 14th, 2023]
- Testing Cancer Immunotherapies on Mice with Human Immune Systems - Mirage News - December 14th, 2023 [December 14th, 2023]
- Georgetown School of Medicine's Department of Immunology Hosts Talk About Therapeutic Vaccine for Autoimmune ... - Georgetown University The Hoya - December 6th, 2023 [December 6th, 2023]
- Long COVID Research Is a Bit of a Mess - Technology Networks - December 6th, 2023 [December 6th, 2023]
- Research Assistant/Research Associate in Immunology job with ... - Times Higher Education - May 13th, 2023 [May 13th, 2023]
- Pioneering learning resource helps academic win top teaching award - Swansea University - May 13th, 2023 [May 13th, 2023]
- 12 Months of Treatment with EPIT Superior to Placebo in ... - UNC Health and UNC School of Medicine - May 13th, 2023 [May 13th, 2023]
- Director of Discover Biology, Neuroscience & Immunology- full-time ... - Merck KGaA - May 13th, 2023 [May 13th, 2023]
- Absci, The Kennedy Institute for immunotherapies development - Pharmaceutical Technology - May 13th, 2023 [May 13th, 2023]
- Customizing T Cell-Based Immunotherapies in a 'SNAP' - UPMC - May 13th, 2023 [May 13th, 2023]
- Understanding Lupus: an interview with the Garvan Institute - News-Medical.Net - May 13th, 2023 [May 13th, 2023]
- Professor Laura Mackay wins LEO Foundation Award in Region ... - The Peter Doherty Institute for Infection and Immunity - May 13th, 2023 [May 13th, 2023]
- Trinity's Prof Ed Lavelle recognised by ISI for vaccine research - SiliconRepublic.com - May 13th, 2023 [May 13th, 2023]
- Allison Institute announces appointment of inaugural members - EurekAlert - May 13th, 2023 [May 13th, 2023]
- Study sheds light on how the immune system protects the body - EurekAlert - May 13th, 2023 [May 13th, 2023]
- Werewolf Therapeutics Reports First Quarter 2023 Financial Results ... - BioSpace - May 13th, 2023 [May 13th, 2023]
- PeaceHealth cuts Bellingham jobs, announces clinic closure and reduces some services - Yahoo News - May 13th, 2023 [May 13th, 2023]
- Help! My skin is itchy - Parkview Health - May 13th, 2023 [May 13th, 2023]
- Takeda reports 12.8% rise in FY2022 revenue - Pharmaceutical Technology - May 13th, 2023 [May 13th, 2023]
- Welcoming a new column: Vasso's corner - The immune system - Neos Kosmos - May 13th, 2023 [May 13th, 2023]
- UC statement on Gov. Newsom's 2023-24 revised budget proposal - University of California - May 13th, 2023 [May 13th, 2023]
- Jasper Therapeutics (JSPR) Appoints Stephen J. Galli to its Board - StreetInsider.com - May 13th, 2023 [May 13th, 2023]
- DICE Therapeutics Reports First Quarter 2023 Financial Results and ... - InvestorsObserver - May 13th, 2023 [May 13th, 2023]
- Cannabis-derived products have flooded US market Two ... - Down To Earth Magazine - May 13th, 2023 [May 13th, 2023]
- NYU Langone Health in the NewsFriday, May 12, 2023 - NYU Langone Health - May 13th, 2023 [May 13th, 2023]
- UNION therapeutics to present at 4th Annual Dermatology Drug ... - InvestorsObserver - May 13th, 2023 [May 13th, 2023]
- Russell Investments Decreases Stake in Argenx SE by 20% in Q4 ... - Best Stocks - May 13th, 2023 [May 13th, 2023]
- How my training helps me to address health disparities in multiple ... - Nature.com - May 13th, 2023 [May 13th, 2023]
- Positive trial results for RSV infant treatment: Sanofi - Medical Xpress - May 13th, 2023 [May 13th, 2023]
- How Can You Find Out If You're Allergic to a Medication Before You ... - Verywell Health - May 13th, 2023 [May 13th, 2023]
- HUTCHMED Announces Appointment of Independent Non ... - GlobeNewswire - May 13th, 2023 [May 13th, 2023]
- The Wistar Institute, Pennsylvania Biotechnology Center and Baruch S. Blumberg Institute Forge Strategic Collaboration to Support Regional Biotech... - May 13th, 2023 [May 13th, 2023]
- Humanized Mouse and Rat Model Market worth $338 million | MarketsandMarkets - Yahoo Finance - May 13th, 2023 [May 13th, 2023]